SG11201704370XA - Low dosage a2a antagonist for the treatment of adhd and parkinsons - Google Patents

Low dosage a2a antagonist for the treatment of adhd and parkinsons

Info

Publication number
SG11201704370XA
SG11201704370XA SG11201704370XA SG11201704370XA SG11201704370XA SG 11201704370X A SG11201704370X A SG 11201704370XA SG 11201704370X A SG11201704370X A SG 11201704370XA SG 11201704370X A SG11201704370X A SG 11201704370XA SG 11201704370X A SG11201704370X A SG 11201704370XA
Authority
SG
Singapore
Prior art keywords
parkinsons
adhd
antagonist
treatment
low dosage
Prior art date
Application number
SG11201704370XA
Inventor
Lone Frydelund Larsen
Johan Areberg
Nathalie Breysse
Gamini Chandrasena
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of SG11201704370XA publication Critical patent/SG11201704370XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
SG11201704370XA 2014-12-03 2015-12-01 Low dosage a2a antagonist for the treatment of adhd and parkinsons SG11201704370XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA201400704 2014-12-03
PCT/EP2015/078181 WO2016087429A1 (en) 2014-12-03 2015-12-01 Low dosage a2a antagonist for the treatment of adhd and parkinsons

Publications (1)

Publication Number Publication Date
SG11201704370XA true SG11201704370XA (en) 2017-06-29

Family

ID=58731664

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704370XA SG11201704370XA (en) 2014-12-03 2015-12-01 Low dosage a2a antagonist for the treatment of adhd and parkinsons

Country Status (25)

Country Link
US (2) US20160158211A1 (en)
EP (1) EP3226863A1 (en)
JP (1) JP2017536400A (en)
KR (1) KR20170090430A (en)
CN (1) CN106999480A (en)
AU (1) AU2015357197A1 (en)
BR (1) BR112017011777A2 (en)
CA (1) CA2966582A1 (en)
CL (1) CL2017001407A1 (en)
CO (1) CO2017004785A2 (en)
CR (1) CR20170221A (en)
DO (1) DOP2017000121A (en)
EA (1) EA201790973A1 (en)
EC (1) ECSP17030050A (en)
IL (1) IL252355A0 (en)
MA (1) MA41090A (en)
MX (1) MX2017007027A (en)
NI (1) NI201700066A (en)
PE (1) PE20170926A1 (en)
PH (1) PH12017500923A1 (en)
SG (1) SG11201704370XA (en)
SV (1) SV2017005441A (en)
TN (1) TN2017000174A1 (en)
TW (1) TW201632186A (en)
WO (1) WO2016087429A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113727999A (en) 2019-01-11 2021-11-30 奥默罗斯公司 Methods and compositions for treating cancer
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
CN114917350B (en) * 2022-06-21 2023-06-13 重庆医科大学附属第二医院 Use of CFTR enhancers in attention deficit and hyperactivity disorder and products

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3002283T1 (en) * 2003-12-26 2018-06-29 Kyowa Hakko Kirin Co., Ltd. Thiazole derivatives
ES2658892T3 (en) * 2008-07-23 2018-03-12 Kyowa Hakko Kirin Co., Ltd. Therapeutic agent for migraine
TWI548411B (en) * 2009-04-28 2016-09-11 Kyowa Hakko Kirin Co Ltd Exercise disorder treatment
UA110097C2 (en) * 2009-09-02 2015-11-25 THERAPEUTIC AGENT FOR TREATMENT OF DISORDERS
UA113383C2 (en) * 2009-09-02 2017-01-25 THERAPEUTIC AGENT FOR TREATMENT OF ANXIETY DISORDERS

Also Published As

Publication number Publication date
IL252355A0 (en) 2017-07-31
US20160158211A1 (en) 2016-06-09
PH12017500923A1 (en) 2017-11-20
SV2017005441A (en) 2017-08-25
CR20170221A (en) 2017-10-05
CN106999480A (en) 2017-08-01
KR20170090430A (en) 2017-08-07
CL2017001407A1 (en) 2018-01-05
EP3226863A1 (en) 2017-10-11
TN2017000174A1 (en) 2018-10-19
JP2017536400A (en) 2017-12-07
MX2017007027A (en) 2017-08-24
WO2016087429A1 (en) 2016-06-09
EA201790973A1 (en) 2017-10-31
MA41090A (en) 2017-10-10
TW201632186A (en) 2016-09-16
ECSP17030050A (en) 2017-08-31
US20180125835A1 (en) 2018-05-10
PE20170926A1 (en) 2017-07-13
NI201700066A (en) 2018-01-04
BR112017011777A2 (en) 2018-02-20
AU2015357197A1 (en) 2017-05-25
DOP2017000121A (en) 2017-07-15
CO2017004785A2 (en) 2017-08-31
CA2966582A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
HK1257955A1 (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
IL258931A (en) Therapeutic compounds and methods
HK1247614A1 (en) Therapeutic compounds and uses thereof
HK1243073A1 (en) Therapeutic compounds and uses thereof
HK1249103B (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
ZA201607415B (en) Antibody-drug-conjugate and its use for the treatment of cancer
HK1244000B (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
HK1253049A1 (en) Glycan-interacting compounds and methods of use
GB201413355D0 (en) Compositons and methods
GB201403093D0 (en) Therapeutic compounds and their use
GB201404470D0 (en) Therapeutic methods and materials
IL283335B (en) Dihydropyrimidin-2-one compounds and medical use thereof
HK1248697A1 (en) Therapeutic compounds and uses thereof
ZA201802256B (en) Compounds and therapeutic uses thereof
HK1232145A1 (en) Bifunctional compounds and use for reducing uric acid levels
IL247325A0 (en) Therapeutic methods employing noribogaine and related compounds
GB201406172D0 (en) Therapy and pharmaceutical composition
IL252355A0 (en) Low dosage a2a antagonist for the treatment of adhd and parkinsons
IL248847A0 (en) Dosage of dasotraline and method for treatment of adhd
GB201418541D0 (en) Materials for use with general hyperthermia treatment
GB201522994D0 (en) The combination of chinese medicine for treating ADHD
GB201501202D0 (en) Novel methods for diagnosis and therapy
GB201410387D0 (en) Compounds and their therapeutic use
GB201403496D0 (en) Compounds and their therapeutic use